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THE STRUCTURE AND FUNCTION OF HUMAN SERUM ALBUMIN IN THE 
NORMAL AND DISEASED STATES 
LINDSEY CLAUS 
ABSTRACT 
   
Human serum albumin (HSA) is the major protein in human serum and an 
important carrier of free fatty acids and small-molecule drugs. Various post-
translationally modified forms of HSA, including glycated and oxidized HSA, are 
implicated in a variety of diseases, including cardiovascular disease and diabetes.  
 In this study, the structure and stability of HSA was investigated through circular 
dichroism and fluorescence spectroscopy. The features of fatty acid-free HSA, fatty acid-
bound HSA, and post-translationally modified protein forms, including cystenylated, 
glycated, oxidized, and glycoxidized HSA, were compared. The pro- or anti-oxidant 
effect of these various forms was studied through examining the oxidation of LDL by Cu 
ions in the presence of each of these forms of HSA.   
The results showed that fatty acid binding did not significantly alter the structural, 
stability or anti-oxidant properties of HSA. However, all post-translational modifications 
of HSA reversed its effect on LDL oxidation: unmodified HSA was clearly anti-oxidant, 
while modified HSA acted as a pro-oxidant by decreasing the lag phase of LDL 
oxidation. To our knowledge, this effect has not been reported previously. The 
biochemical and structural basis underlying this general effect and its relevance to 
various oxidation processes in vivo remains to be determined in the future. As the 
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modified forms of HSA studied here are implicated in a variety of disease states, these 
studies could suggest significant changes to the functional properties of human serum 
albumin resulting from these post-translational modifications.    
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CHAPTER 1: INTRODUCTION 
 
Human serum albumin (HSA), the most common protein in human serum, has 
many important physiological roles including the maintenance of colloid osmotic 
pressure, the transport of fatty acids,1 the maintenance of blood pH,2 and an anti-oxidant 
function.3 Albumin also has a central role in transporting many pharmacological 
substances throughout the body, including ibuprofen, warfarin, and many other drugs.4 
Thus, the study of the structure and function of HSA has many wide-ranging 
implications.    
 
1.1 The structure of human serum albumin 
HSA is a 66.5kD, 585 amino acid polypeptide composed of three homologous 
domains thought to originate from a triplicated ancestral gene.5 Each domain of HSA can 
be divided into subdomain A (containing six α-helices) and subdomain B (containing 
four α-helices). HSA has ~68% α-helical content, some random coil secondary structure, 
and essentially no β-sheet secondary structure6; Figure 1A shows a cartoon depiction of 
albumin color-coded by secondary structure.7  
In 1992, He and Carter first published the crystal structure of albumin determined 
to 2.8 Å resolution.8 More recently published crystal structures are of albumin complexed 
with various small molecules, including simple fatty acids such as myristate (Figure 1B).9 
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Figure 1.1: The 3-D Structure of HSA 
 (1A) This ribbon diagram shows the crystal structure of HSA generated from the PDB 
which depicts the high α-helical content of the protein.7  
(1B) A depiction of HSA illustrating myristate bound at five major fatty acid binding 
pockets, adapted from Mandelkow et al.9 Protein domains are color-coded. 
 
1.1.1 Fatty acid binding sites 
One of albumin’s main functions is to carry fatty acids (FAs) and other small 
hydrophobic molecules through the blood. Albumin contains at least seven moderate-to-
high-affinity binding sites for fatty acids, with various sources differing in their 
A 
B 
α-helix 
turn 
random coil 
Domain IA 
Domain IB 
Domain IIA 
Domain IIB 
Domain IIIA 
Domain IIIB 
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descriptions of some of the lower affinity sites.1,10-12 Figure 1B shows a ribbon diagram 
of albumin with bound molecules of myristate in five of its fatty acid binding sites9.  
As albumin composes around ~60% of all proteins in human serum,1 knowledge 
of its fatty acid binding sites has been used to design drugs that can circulate through 
plasma bound to albumin at these sites. Also, since albumin circulates through plasma 
with a half-life of 19 days, it is an especially attractive potential drug carrier. One drug 
utilizing this mechanism, detemir, is a myristic acid derivative of insulin used to treat 
diabetes.13 Treatment with detemir as an insulin analogue avoids the typical insulin peak 
seen with insulin replacement therapy, because detemir circulates bound to albumin and 
thus maintains protracted activity for hours after delivery.13 
 
1.1.2 Drug binding sites of HSA 
In 1975, Sudlow et al. described two drug binding sites of albumin now called 
Sudlow sites I and II, in domains IIA and IIIA, respectively.14,15  Both of these binding 
sites are located in hydrophobic cavities within their subdomain.6 Sudlow site I is able to 
bind a variety of ligands due to flexibility in the binding site shape; one important ligand 
for this site is the drug warfarin.16 Sudlow site II also binds a variety of molecules, 
especially aromatic carboxylates such as benzodiazepines.14 Regions of the Sudlow sites 
also correspond to two of the seven commonly described high-affinity fatty acid binding 
sites of albumin.17 
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1.1.3 The free thiol of Cys-34 
Albumin contains 35 cysteine residues which form 17 disulfide bridges, with the 
free thiol of Cys-34 able to participate in redox reactions.18 This thiol can be oxidized by 
the formation of a disulfide bond with a free cysteine residue or glutathione, forming a 
form of albumin called non-mercapto-albumin (HNA), which is distinguished from the 
reduced form human mercapto-albumin (HMA). Cys-34 can also be irreversibly oxidized 
to form sulfinic acid (Cys-SO2H) or sulfonic acid (Cys-SO3H). HSA has 6 methionine 
residues, which can also undergo oxidation.17-8 
The free thiol of Cys-34 comprises about 80% of the free thiols present in the 
plasma.19 As this residue is relatively far from the Sudlow I and II drug binding sites, it is 
an attractive binding target for new drug design.20  
 
1.1.4 Glycation of HSA  
 Glycation, the non-enzymatic addition of a carbohydrate to a protein or lipid, is 
one potential modification of HSA in plasma. HSA can undergo glycation via the 
addition of reducing sugars to the amine groups of lysine or arginine residues or the N-
terminus of the protein.21  
Early stage glycation occurs when a primary amine group of HSA is attacked by a 
nucleophilic reducing sugar, resulting in Schiff base formation and the linearization of 
the reducing sugar. Then, the 2-OH group of the Schiff base can be oxidized to a ketone, 
forming the ketoamine Amadori product. This product can become further modified via a 
variety of processes, including oxidation. These modifications often result in the 
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formation of intermediate products that can react with positively charged arginine and 
lysine residues. This can ultimately cause cross-linking of the albumin protein that leads 
to significant disruptions in the protein’s structure.21 
 The measurement of levels of glycated albumin in the serum of diabetic patients 
has become a common means of examining glycemic control. Diabetes refers to a family 
of disorders in which insulin signaling pathways are disrupted, causing unusually high 
serum glucose levels. Especially when diabetes is under poor glycemic control, and blood 
glucose levels are consistently aberrantly high, increased amounts of albumin become 
glycated, which can affect protein function.21 
 
1.1.5 Aromatic residues of HSA  
 HSA contains one tryptophan residue, Trp-214, in subdomain IIA.6 This residue is 
located near the Sudlow I site. Therefore, local changes in the environment of this residue 
may result in changes to this binding site.  
 
1.2 Oxidative processes in plasma  
 Cardiovascular disease is the leading cause of death in the United States; a major 
cause of cardiovascular disease is atherosclerosis, the narrowing of arteries due to plaque 
buildup.22 It has long been known that high levels of reactive oxygen species (ROS) such 
as H2O2 in the blood can contribute to the development of atherosclerosis through a 
variety of mechanisms including disrupting cell membrane integrity, promoting ECM 
protein production, and promoting inflammation.23 One particularly important step in the 
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formation of atherosclerotic plaques occurs when ROS oxidize lipoprotein particles in the 
blood, as described below. 
 
1.2.1 Lipid circulation via lipoprotein transport 
 While albumin is the primary vehicle in the blood carrying small hydrophobic 
molecules such as free fatty acids, the primary method of lipid circulation is via 
lipoproteins, which are macromolecular assemblies of specific proteins (apolipoproteins) 
and various lipids. These assemblies differ in terms of particle size, density, protein and 
lipid composition and function. They are named according to their density: Very Low, 
Intermediate, Low, and High-Density Lipoproteins (VLDL, IDL, LDL, and HDL), with 
HDL containing the highest protein:lipid ratio.24  
 VLDL is assembled in the liver from the assembly of apolipoprotein B, 
phospholipids, triglycerides, and cholesterol. These particles then circulate through the 
bloodstream, where lipoprotein lipase hydrolyzes triglycerides, decreasing the lipid 
content of VLDL. This process converts VLDL to IDL as the protein:lipid ratio of the 
assembly increases. Under normal physiological conditions, ~50% of IDL particles are 
taken up by the liver before they become LDL; the rest continue to lose triglyceride 
content in the bloodstream and are termed LDL when their cholesterol content is higher 
than their triglyceride content.25  
 While LDL particles are responsible for bringing cholesterol from the liver to the 
peripheral tissues, High-Density Lipoproteins (HDL) perform the opposite function: the 
transport of cholesterol back to the liver.26 The ratio of LDL/HDL is used by many as an 
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indicator of potential cardiovascular disease.26 One reason for this is the problems that 
can result from a surfeit of LDL, especially oxidized LDL, in the blood. 
 
1.2.2 The deleterious process of LDL oxidation  
 The potential relevance of oxidized LDL to the development of atherosclerotic 
plaques has been studied since it was noted in the 1980’s that the incubation of 
macrophages with oxidized LDL produces cholesterol buildup, while the incubation of 
macrophages with unmodified LDL does not.27 Oxidized LDL refers to a form of LDL in 
which the triglyceride, cholesterol, and apolipoprotein components of the assembly 
become oxidized by a variety of potential mechanisms. The oxidation of apolipoprotein 
components typically generates modifications including altered cysteine, methionine, 
lysine, and arginine residues, which can cause abnormally cross-linked polypeptides.28 
The oxidation of lipid components leads to the formation of molecules including fatty 
acid peroxides and hydroxides, hydrocarbons, 7-ketocholesterol, and other products of 
cholesterol oxidation.28 
 Because of these alterations, oxidized LDL is taken up by macrophages at a faster 
rate than normal LDL. This can lead to the build-up of foam cells, macrophages with a 
high lipid content, along the arterial wall. This buildup directly contributes to the 
formation of atherosclerotic plaques, which mature as foam cells secrete pro-
inflammatory cytokines. Eventually, a fibrous cap forms over the plaque; the rupture of 
this cap can lead to blood clotting and dangerous arterial occlusion.28  
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Anti-oxidant substances in blood can oppose this process by reducing the amount 
of free ROS in the circulation. In particular, the ability of plasma albumin to undergo 
oxidation, as described in 1.1.3, means that albumin can be thought of as a buffer in 
plasma to regulate the levels of reactive oxidative species in the blood, reducing the 
harmful effects of these substances. The free thiol of Cys-34 comprises about 80% of the 
free thiols present in the plasma, giving HSA a central role in regulating the levels of 
ROS in plasma.18 
To investigate the anti-oxidant function of HSA, we performed in vitro studies to 
determine the potential effect of unmodified HSA, fatty acid-bound HSA, and various 
post-translationally modified forms of HSA on the oxidation of LDL by copper. 
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CHAPTER 2: METHODS 
2.1 Protein samples 
 
Samples of HSA-1 (catalog # A9511), HSA-2 (catalog # A1887), and glycated 
albumin (catalog # A8301) used in this study were purchased from Sigma Aldrich. Stock 
solutions of albumin were prepared at 5 mg/mL protein concentrations in 10 mM 
phosphate buffer (PB), pH 7.5-7.7, and these samples were dialyzed extensively against 
PB to remove preservatives.  
The concentration of protein samples was measured with absorbance spectroscopy, 
measuring the absorption of UV light at wavelength ƛ = 280 nm. The absorbance 
intensity was compared with a value generated from Beer’s Law, A = εcl, using the 
protein concentration c mg/mL, the cell path length l cm, and the known extinction 
coefficient of albumin ε = 35219 M-1 cm-1.29 
 
 
2.2 Circular dichroism spectroscopy  
 
2.2.1 An introduction to CD spectroscopy 
 Circular dichroism (CD) spectroscopy is a well-known method used to investigate 
the secondary structure of proteins. In a CD experiment, circularly-polarized light is 
passed through a sample, and the differential degree of absorption of left- and right-
handed circularly polarized light is determined. This difference can be substantial for any 
chiral sample, including polypeptides (as all amino acids except glycine exhibit chirality). 
In particular, in the far-UV region (190-250 nm), the primary chromophore in a protein is 
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the peptide bonds of the polypeptide backbone.30 Therefore, far-UV CD spectra report on 
the secondary structure of proteins. 
Regular structural features of the protein backbone lead to characteristic features 
in far-UV CD spectra: an α-helical structure is indicated by two minima at 208 nm and 
222 nm and a maximum at 192 nm; the β-pleated sheet CD spectrum is characterized by a 
minimum at 217 nm and a maximum at 198 nm; the random coil structure is indicated by 
a minimum at ~200 nm.30-32 Figure 2 depicts the typical CD spectra of polypeptides 
exhibiting a fully α-helical, β-pleated sheet, or random coil secondary structure.30 Of 
course, most proteins consist of varying degrees of these different secondary structure 
components, resulting in a signal that can be seen as a combination of the contributions of 
these various structural components. In particular, albumin has been characterized to be 
about 60% α-helical in content, with very little β-pleated sheet, and most of the rest of the 
protein consisting of a random coil secondary structure. 33   
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Figure 2.1: Circular dichroism spectra characteristic for protein secondary structures 
 
Here are the CD spectra of model peptides with secondary structure consisting of entirely 
one type. Adapted from30. 
 
 
 Since CD spectroscopy is a useful tool to measure protein secondary structure, the 
measurement of a CD signal during heating of a sample can be used to monitor protein 
unfolding from a native into a random coil structure to thereby study protein stability. In 
particular, measuring ellipticity at one wavelength over the course of a thermal melt can 
provide useful information about the potential loss of secondary structure characteristics 
that cause a signal at that wavelength. For a protein with significant α-helical structure, 
this can be done by measuring ellipticity at 222 nm over the course of a melt, since a 
difference in absorption of left and right-circularly polarized light for protein samples at 
this wavelength is almost entirely due to the α-helical content of the protein’s secondary 
structure. 
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2.2.2 Method for CD spectroscopy in this study 
CD Spectroscopy was performed with an AVIV-450 spectrometer. Unless 
otherwise stated, albumin with a concentration of 0.1 mg/mL was dissolved in 10 mM PB 
at pH 7.7 at room temperature and was placed in a 0.1 mm path length cell. Far-UV CD 
spectra were recorded at room temperature from 190 nm to 250 nm. The α-helical content 
of a protein was estimated from the measured value of the molar residue ellipticity at 222 
nm, [Ɵ222], with the equation % α-helix = [(−[Θ]222 + 3,000)/39,000] × 100.33  
For thermal denaturation (melting) experiments, CD signal, which was reported as 
ellipticity (Ɵ), was recorded at 222 nm. Heating was performed at a rate of 2 °C per min 
from 25 °C to 90 °C, followed by cooling to room temperature at the same rate.  
 
2.3 Fluorescence spectroscopy 
2.3.1 An introduction to fluorescence spectroscopy  
 Fluorescence spectroscopy is another well-known method used to investigate 
protein structure. In a fluorescence spectroscopy experiment, fluorophores absorb 
radiation at a specific wavelength and then, after a time interval called the fluorescence 
lifetime, radiation from a lower energy level (longer wavelength) is emitted. Due to their 
electronic structure, aromatic side chains of proteins absorb UV light more than any other 
protein residues; phenylalanine residues do so weakly, so the major features of albumin 
that respond to UV excitation are the Trp-214 residue and tyrosine residues. Emission at 
295 nm is selectively absorbed by tryptophan residues, and 280 nm excitation is absorbed 
by both tryptophan and tyrosine residues.34 
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Therefore, the emission spectra of HSA at 295 nm excitation can be used to 
examine the local environment of the Trp-214 residue. When albumin is in the folded 
state, Trp-214 is buried in an internal hydrophobic pocket, though when albumin unfolds, 
this arrangement is disrupted. When this occurs, the maximum of the fluorescence 
emission typically undergoes a red shift from ~335 nm to 350 nm, which reflects an 
increased polarity near Trp-214 resulting from its increased solvent exposure upon 
unfolding. Thus, the change in the ratio of fluorescence intensity at 335 nm to 350 nm 
can be used to assess the environment of Trp-214 and the degree to which albumin is in 
its native state or an unfolded state.34 
 Fluorescent probes can also be used to study the conformational state of a protein; 
in particular, the fluorescent dye 1-anilinoaphthalene-8-sulfonate (ANS) is known to bind 
to large hydrophobic pockets of proteins.35 In 1954, Stryer showed that in the presence of 
buffer, this dye fluoresces weakly, but when bound to a hydrophobic pocket of 
apohemoglobin, an increased emission is produced at wavelength ƛ = 450 nm.36  
 When ANS binds to a hydrophobic pocket of HSA, excitation of Trp-214 at  
ƛ = 295 nm can lead to a transfer of energy to ANS and a fluorescence emission 
maximum at ƛ ~ 450 nm.37 The mechanism for effect is Förster resonance energy transfer 
(FRET), a useful method to test the spatial proximity of specific pairs of fluorophores. 
FRET occurs if the emission spectrum of the donor overlaps with the absorption 
spectrum of the acceptor.34 Then the light emitted by the donor is absorbed by the 
acceptor and re-emitted at a lower energy (shorter wavelength). This happens when the 
donor and a fluorophore acceptor are within approximately 10 nm of each other (the 
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distances are different for different donor-acceptor pairs), yet at longer distances the 
energy transfer cannot occur. In an ANS-HSA FRET experiment, the intrinsic 
fluorescence of the Trp-214 residue of HSA (emission maximum at 340 nm) functions as 
the donor and ANS as the acceptor (emission maximum at 450 nm).37
 
Figure 2.2: FRET from Trp to ANS is facilitated by the overlap in the absorption 
spectrum of ANS and the emission spectra of Trp 
 
Here the emission spectrum for Trp-214 of HSA (excitation wavelength ƛ = 295 nm) is 
plotted next to the absorption spectrum of ANS. The clear spectral overlap between Trp 
emission and ANS absorption at ~350 nm allows for FRET from Trp-214 to ANS. 
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2.3.2 Fluorescence spectroscopy experiments in this study 
 Fluorescence spectroscopy experiments, excluding the Guanidine Hydrochloride 
(Gd HCl) denaturation experiments, were performed using a Varian Cary Eclipse 
spectrofluorometer with a 5 mm path length cell. Experiments were performed using  
0.1 mg/mL of protein dissolved in 10 mM PB at pH 7.7. To measure the intrinsic 
fluorescence of HSA-1 and HSA-2, an excitation wavelength of ƛex = 280 nm was used to 
measure the contributions of tyrosine and tryptophan residues, and ƛex = 295 nm was used 
to measure the contribution of tryptophan alone. Emission spectra were recorded from 
310 nm to 500 nm. 
 For fluorescence experiments using HSA and ANS, an excitation wavelength of 
ƛex = 295 nm was used and emission spectra were recorded from 310 to 650 nm. First, 
samples of ANS were dissolved alone in 10 mM PB at pH 7.7, and the low intensity 
emission spectra for ANS was recorded. Then, ANS at varying concentrations in PB was 
added to samples of HSA at 0.1 mg/mL at pH 7.7. The sample was excited at ƛex = 295 
nm (to directly excite ANS), and the emission spectra were recorded from 310 to 650 nm.  
 
2.3.3 Gd HCl denaturation experiments 
 The denaturation of proteins with Gd HCL is a useful means to study protein 
stability. In these experiments, the loss of protein structure upon increasing denaturant 
concentrations is monitored at a constant temperature.  
0.1 mg/mL samples of HSA-1 and HSA-2 were incubated overnight at room 
temperature with 1 - 6 M Gd HCl in 10 mM PB at pH 7.7. A TECAN fluorescence plate 
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reader was used to measure the fluorescence intensity of these samples. Excitation at ƛ = 
295 nm was used to measure emission at 335 nm and 350 nm.  
 
 
2.4 LDL oxidation experiments 
2.4.1. LDL oxidation by Cu+ 
 
 The oxidation of LDL by transition metals such as Copper is a commonly studied 
in vitro method of LDL oxidation. This reaction proceeds with three defined phases: the 
lag phase, the propagation phase, and the saturation phase. During the lag phase, free 
radicals are destroyed by anti-oxidants. Then, during the lag phase, a peroxidation chain 
reaction occurs in which unsaturated fatty acids contained within LDL are oxidized to 
hydroperoxides. This causes an increase in the level of conjugated dienes in the sample, 
which is significant because the absorbance of an LDL sample at 234 nm is typically low 
but is greatly increased with the formation of conjugated dienes. Therefore, the level of 
absorbance at 234 nm can be measured to track the kinetics of this reaction.38,39  
 
2.4.2. Method for LDL oxidation experiments in this study 
 LDL (apoB concentration 0.1 mg/mL ) in 10 mm PB at pH 7.5 was equilibrated at 
37 °C. Then, 10 μm of CuSO4 was added to initiate the oxidation reaction. The reaction 
kinetic was monitored using a Varian Cary Eclipse spectrofluorometer with a 5 mm path 
length cell by measuring the absorbance at 234 nm at 37 °C. LDL oxidation in the 
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presence of albumin was performed under identical conditions with 0.1 mg/ml of 
albumin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
 
CHAPTER 3: EFFECTS OF FATTY ACID BINDING ON THE STRUCTURE OF 
HUMAN SERUM ALBUMIN 
 
 
3.1 Effects of free fatty acid binding on the secondary structure and thermal 
stability of HSA analyzed by far-UV CD spectroscopy  
Far-UV CD spectra were recorded for 0.1 mg/mL albumin samples to examine 
the secondary structure of HSA with and without fatty acids bound, termed HSA-1 and 
HSA-2, respectively. As shown in Figure 3A, the spectra of HSA-1 and HSA-2 both 
show characteristic aspects of an α-helical signal: minima at 208 nm and 222 nm and a 
maximum at 192 nm. There was no significant difference found between the spectra for 
the FA-bound and unbound forms of HSA. Both have an α-helical content of ~60%, 
calculated as described in 2.2.2. Therefore, the secondary structure of HSA was not 
significantly changed upon free fatty acid binding. 
Then, to examine the relative stability of HSA-1 and HSA-2, a CD melt was 
performed with ellipticity [Ɵ] measured at ƛ = 222 nm. Given that the signal at 222 nm 
for an α-helical protein should be a minimum of the far-UV spectrum, measurements 
were taken at this value to monitor the disruption of secondary structure during heating. 
There was no significant difference in the melting curves of the fatty acid-bound and 
unbound forms of HSA. Therefore, thermal stability of HSA did not significantly change 
upon free fatty acid binding.   
Also, samples of HSA-1 and HSA-2 both showed hysteresis. One likely 
explanation for this is that proteins often aggregate upon thermal denaturation; such 
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aggregation will not be reversed upon cooling of the sample. Thus, both FA-bound and 
unbound forms of HSA showed irreversible unfolding during the thermal melt.  
 
 
Figure 3.1: The effect of fatty acid binding on the secondary structure and stability of 
HSA 
(3A): Far-UV CD spectroscopy performed with 0.1 mg/mL albumin dissolved in PB as 
described in 2.2.2. The spectra show no significant difference between HSA-1 (with 
bound FA) and HSA-2 (without FA). 
(3B): 0.1 mg/mL samples of HSA-1 and HSA-2 were heated and then cooled at a rate of 
2 °C/min while the CD signal at 222 nm was measured.  
 
 
 
 
A B 
melting 
cooling 
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3.2 Effects of free fatty acid binding on the environment of Trp-214 in HSA 
analyzed by intrinsic Trp fluorescence  
 The intrinsic fluorescence of fatty acid-bound and fatty acid-free forms of HSA 
was measured to see if there were differences in the local environment of the aromatic 
residues of HSA-1 and HSA-2. Figure 3.2 shows the emissions spectra generated for 
samples of HSA-1 and HSA-2 with an excitation wavelength of either ƛ = 280 nm 
(Figure 3A) or ƛ = 295 nm (Figure 3B). Excitation at ƛ = 280 nm was performed to 
measure the intrinsic Trp fluorescence of the protein due to tyrosine and tryptophan 
residues, and excitation at ƛ = 295 nm was performed to solely excite Trp-214. For 
excitation at both wavelengths, the unbound form of HSA had an emission maximum 
~1.5 times that of the fatty-acid bound form of HSA, and the wavelength of this emission 
maximum was the same for HSA-1 and HSA-2. This difference in emission may result 
from various factors which require further investigation. However, the observation that 
the wavelength of the maximal fluorescence remained invariant indicates that the polarity 
near Trp-214 (and hence, its solvent exposure) did not significantly change upon FA 
binding.  
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Figure 3.2: The effect of fatty acid binding on the intrinsic fluorescence of HSA 
Intrinsic fluorescence experiments performed as described in 2.3.2; 0.1 mg/mL of 
albumin was dissolved in 10 mM PB at pH 7.7, and excitation at ƛex = 280 nm (A) and  
ƛex = 295 nm (B) was performed to measure the fluorescence intensity of FA-bound 
albumin (HSA-1) and FA-unbound albumin (HSA-2).  
 
 
3.3 Effect of free fatty acid binding on structural stability of HSA at an ambient 
temperature analyzed by chemical denaturation  
 
 A guanidine hydrochloride (Gd HCl) denaturation study was performed to 
compare by an independent method the stability of HSA-1 and HSA-2. Samples of HSA-
1 and HSA-2 were incubated overnight at room temperature with various concentrations 
of Gd HCl dissolved in standard buffer. After this incubation period, the fluorescence 
emission of these samples due to excitation at ƛ = 295 nm was measured. The ratio of 
emission at 335 nm / 350 nm was measured to determine the relative degree of exposure 
of the Trp-214 residue to the solvent environment, as described in 2.3.2. There was no 
A  B 
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significant difference in the sigmoidal curves generated for the bound and unbound form 
of HSA (Figure 3.3); this suggests that both forms have similar stability.   
 
Figure 3.3 The chemical denaturation of FA-bound (HSA-1) and unbound (HSA-2) 
albumin 
 
0.2 mg/mL samples of HSA-1 and HSA-2 were dissolved in 10 mM Pb at pH 7.7 and 
incubated with 1 -6 M Gd HCl. The plots of 335 nm / 350 nm emission intensity as a 
function of Gd HCl concentration for HSA-1 and HSA-2 both show a clear sigmoidal 
shape, indicating a cooperative protein unfolding with a transition midpoint circa 2.5 M 
Gd HCl. 
 
 
 
3.4 ANS binding to HSA-1 and HSA-2 
 
 To examine potential differences in tertiary structure for HSA-1 and HSA-2, the 
hydrophobic probe 1-anilinonaphthalene-8-sulfonate (ANS) was used to examine the 
hydrophobic cavities of albumin. Samples containing 20 μm ANS and 0.1 mg/mL 
albumin in standard PB were excited at either ƛ = 360 nm or ƛ = 295 nm to test either 
direct ANS emission or the emission of ANS induced by the Forster resonance energy 
transfer (FRET) from Trp-214, respectively.  
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  Figure 3.4A shows the fluorescence emission spectra of ANS bound to albumin 
and excited at ƛ = 360 nm; the emission signal due to ANS alone is weak, especially 
when compared to the signal from ANS bound to albumin (the black and dark gray lines). 
In the bound form, ANS shows specific spectral characteristics as compared to unbound 
ANS, including a ~65 nm red-shift (indicating decreased polarity upon ANS transfer 
from solution to the HSA binding site) and significant increase in emission intensity (due 
to decreased quenching of ANS by the solvent). Comparing the emission due to ANS 
bound to HSA-1 or HSA-2, there was no change in the emission wavelength of ANS  
(ƛem = 475 at ƛex = 360 nm). This means that there is no significant difference in the 
polarity of the ANS binding site between the fatty acid-bound and FA-free forms of 
HSA. Nevertheless, there was a significant difference in emission intensity, where ANS 
bound to HSA-1 has an emissions intensity 1.5 times that of ANS with HSA-2. The exact 
cause for this intensity difference is unclear. However, the overall spectral similarity for 
ANS bound to HSA-1 and HSA-2 suggests that ANS does not directly compete with the 
fatty acids bound to HSA-1 at the same binding site. 
 These samples of ANS and albumin were also used to measure FRET from Trp to 
ANS using ƛex = 295 nm to excite Trp-214. Figure 3.4B and 3.4C show the representative 
FRET data for HSA-1 and HSA-2 in standard buffer. First, as expected, the control 
sample of ANS in buffer did not show any significant emission at this excitation 
wavelength. However, upon ANS binding to either HSA-1 or HSA-2, we only saw ANS 
emission at ~ 450 nm, with a complete loss of the Trp emission signal at 340 nm (Figure 
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3.4B and C). Therefore, we observed a nearly complete energy transfer from Trp to ANS, 
so the ANS binding site(s) must be close to Trp-214 in both HSA-1 and HSA-2. 
 
Figure 3.4: The effect of fatty acid binding on hydrophobic regions of albumin 
Fluorescence experiments were performed as described in 2.3.2. 20 μm ANS was 
dissolved in 10 mM PB at pH 7.7, both alone and with 0.1 mg/mL of HSA-1 and HSA-2. 
Panel A shows direct emission from ANS at ƛex = 360 nm. Panels B and C show FRET 
from Trp-214 to ANS using ƛex = 295 nm. FRET experiments using HSA-1 and HSA-2 
are shown in panels B and C, respectively. 
 
 
 In summary, our studies indicated structural and stability properties of FA-bound 
and FA-free forms of HSA. CD spectra showed no significant differences in secondary 
A 
 
B 
C 
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structure between HSA-1 and HSA-2. Stability studies using thermal and chemical 
denaturation showed no significant changes in HSA stability upon fatty acid binding. 
Studies of the intrinsic Trp emission of HSA and indirect emission via bound ANS 
showed differences in fluorescence intensity between HSA-1 and HSA-2 but no clear 
indication of specific structural differences. We conclude that fatty acid binding to HSA 
does not cause any substantial changes in the protein structure and stability.  
 
3.5: LDL oxidation in the presence of HSA-1 or HSA-2 
 
 Next, we studied the potential effects of fatty acid binding on one of the functions 
of albumin, which is its ability to act as an anti-oxidant. To measure the effects of fatty 
acid binding on the anti-oxidant properties of HSA, copper-induced oxidation of low-
density lipoprotein (LDL) was performed in the absence or in the presence of albumin. 
LDL particles containing 0.1 mg/mL apoB were dissolved in standard buffer, and then 
CuSO4 was added. The kinetics of the resulting oxidation reaction were monitored at  
37 °C by measuring the absorbance of UV light at 234 nm, as the conjugated dienes 
formed by this reaction absorb at this wavelength.38 After measuring the rate of this 
reaction with just Cu and LDL, the experiment was run again with 0.1 mg/mL of either 
HSA-1 or HSA-2 added. As the solid black and grey curves of Figure 3.5 show, the 
addition of HSA-1 or HSA-2 to this reaction slowed the oxidative process. Therefore, 
albumin with or without fatty acids bound can have an anti-oxidant effect on LDL. 
In particular, the delay in LDL oxidation upon addition of albumin occurs during 
the lag phase of this reaction. This suggests that the anti-oxidant effect of HSA is due to 
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the decreased interactions of the Cu2+ ions and the LDL. This could result from Cu2+ 
binding to HSA instead of LDL. In fact, HSA has a Cu2+ binding site formed by the N-
terminal residues.6  
Importantly, our results show that there is no significant difference between the 
anti-oxidant effects of HSA-1 or HSA-2, suggesting that the anti-oxidant effect of 
albumin on LDL is not significantly influenced by the fatty acid binding to albumin. This 
suggests that the binding of fatty acids to albumin does not interfere with the interaction 
between albumin and Cu2+ ions. 
 
Figure 3.5: The effect of HSA-1 and HSA-2 on LDL oxidation 
 
LDL containing 0.1 mg/mL protein was dissolved in 10 mm PB at pH 7.5; for 
experiments run with albumin, 0.1 mg/mL of either HSA-1 or HSA-2 were added. At 
time t=0, 10 μm of CuSO4 was added, and the UV absorbance at 234 nm was measured as 
a function of time. 
 
 
 
 
 
 
 
 
1 2 3
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CHAPTER 4: EFFECTS OF POST-TRANSLATIONAL MODIFICATIONS ON 
THE STRUCTURE OF HUMAN SERUM ALBUMIN 
 
  
4.1 Effects of cystenylation of HSA on the structure and anti-oxidant properties of 
albumin 
 
 The free thiol group of Cys-34 in human serum albumin performs a significant 
anti-oxidant role by reducing levels of free radicals in plasma. Therefore, we modified 
Cys-34 in a controlled reaction with glutathione and analyzed the impact of this 
modification on the structure and function of HSA.  
The Cys-34 residue is located on the protein surface and is exposed to solvent, as 
shown in Figure 4.1. To examine structural and functional effects of modifying this 
residue, we incubated HSA samples with glutathione and then performed structural 
studies to compare these samples to the unmodified HSA-1 and HSA-2. We also 
considered possible functional effects of this cystenylation by examining the oxidation of 
LDL in the presence of cys-HSA as compared to in the presence of the unmodified 
protein. 
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Figure 4.1: The location of the free Cys-34 residue in HSA 
(A)The crystal structure of HSA is shown, with disulfide bonds in yellow and the free 
Cys-34 residue in red.  
(B) The local structure of the region of subdomain IA containing Cys-34 is shown, with 
the free cysteine again in red. Adapted from40. 
 
 
4.1.1 The cystenylation process 
 
 A similar process was performed to separately produce cystenylated samples of 
HSA-1 and HSA-2. 100 mM glutathione was added to 5 mg/mL of HSA in 10 mM PB, 
pH 7.5, and the reaction mixture was incubated at 50 °C for 30 minutes. Then, the 
mixture was extensively dialyzed against standard buffer.  
 
4.1.2 Secondary structure and stability of cystenylated albumin 
 First, the secondary structure of cystenylated albumin (cys-HSA) was compared 
with that of unmodified HSA. Far-UV CD spectra were recorded for 0.1 mg/mL of cys-
HSA-1 and cys-HSA-2. The CD spectra for cys-HSA-1 and cys-HSA-2 both show a 
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significant loss of α-helical secondary structure as compared to unmodified HSA-1 and 
HSA-2. Further study will be required to determine the precise reason for this change, as 
the cystenylation process required incubation of the sample at 50 °C for thirty minutes, 
and this could cause denaturation and aggregation of the albumin protein, which would 
then decrease the α-helical character of the CD signal of the sample. Therefore, this CD 
change is probably due to some combination of the change in protein structure due to 
cystenylation and the aggregation of the HSA sample during the modification process. 
Next, a CD melt was performed with ellipticity [Ɵ] measured for ƛ = 222 nm for 
the cys-HSA-1 sample (Figure 4.2B). As with the melting data for unmodified albumin, 
this sample showed hysteresis, probably resulting from protein aggregation upon cooling. 
Comparison of this data with the melting data for HSA-1 shows no significant difference 
in stability between the two samples. 
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Figure 4.2: The effect of cystenylation on the secondary structure and stability of HSA 
(A) Far-UV CD spectra were recorded with 0.2 mg/mL cys-HSA-1 (purple) and cys-
HSA-2 (pink) dissolved in PB. These spectra were compared with those for HSA-1 and 
HSA-2 (black) shown in Figure 3.2. 
(3B): 0.2 mg/mL of cys-HSA-1 was heated and then cooled at a rate of 2 °C/min while 
the CD signal at 222 nm (purple) was measured. This melting curve was compared with 
that for HSA-1 (black). 
 
 
 
A 
B 
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4.1.3 Chemical denaturation of cystenylated albumin with Gd HCl 
 Next, a chemical denaturation experiment was performed using Gd HCl to 
compare the stability of cys-HSA-1 and cys-HSA-2 samples under the same conditions as 
those used for the chemical denaturation experiments for HSA-1 and HSA-2. Comparing 
native FA-bound and FA-free forms of HSA with cystenylated FA-bound and 
cystenylated FA-free forms of HSA, there is no significant difference in structural 
stability. This result is in concordance with the result of the CD melt, which also showed 
no significant difference in structural stability following this post-translational 
modification. 
 
Figure 4.3: The chemical denaturation of cystenylated HSA 
 
0.2 mg/mL samples of cys-HSA-1 and cys-HSA-2 in 10 mM PB at pH 7.7 contained   
0 -6 M Gd HCl, as described in 2.3.3. The plots of 335 nm / 350 nm emission intensity as 
a function of Gd HCl concentration are shown for intact and cystenylated HSA-1 (A) and 
HSA-2 (B). The plots show a clear sigmoidal shape with a transition midpoint circa 2.5 
M Gd HCl, which is similar for all HSA samples. 
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4.1.4 The effects of cystenylation on the anti-oxidant properties of HSA 
 
 We performed the oxidation of LDL in the presence of cys-HSA-1 and  
cys-HSA-2 to see if the cystenylation of the protein affects its anti-oxidant function. This 
reaction was performed exactly as described in 2.4.2 using the modified forms of the 
albumin protein. Figure 4.4 shows the results of LDL oxidation in the presence of cys-
HSA-1 (A) and cys-HSA-2 (B) as compared with oxidation in the presence of 
unmodified albumin and without any albumin added. In contrast to unmodified HSA-1 
and HSA-2, which delay the oxidation of LDL, both modified forms of HSA have a pro-
oxidant effect.  
 Both cys-HSA-1 and cys-HSA-2 seemed to significantly decrease the lag phase. It 
is difficult to determine the exact cause of this change; however, since the effect of HSA-
1 and HSA-2 seems to be a delay of the lag phase due to copper binding to HSA, it is 
clear that this effect does not occur in the presence of cys-HSA-1 and cys-HSA-2. 
Therefore, this result suggests that there is reduced copper binding to the cystenylated 
forms of HSA as compared to the unmodified forms. This could be due to the irreversible 
thermal denaturation of the protein sample during the cystenylation process or due to a 
change in HSA structure caused by the post-translational modification itself, which 
affects the copper binding site. 
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Figure 4.4: The effect of cystenylation on the anti-oxidant properties of HSA 
 
LDL oxidation reactions were performed using the same procedure as described in 3.5: 
0.1 mg/mL of apoB in LDL was dissolved in 10mm PB at pH 7.5, and for experiments 
run with cystenylated albumin, 0.1 mg/mL of cys-HSA-1 (A) and cys-HSA-2 (B) were 
added. Then, 10 μm of CuSO4 was added. The absorbance of 234 nm UV light was 
measured as a function of how much time had passed since the Copper Sulfate was 
added.  
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4.2 Effects of oxidation of HSA on the structure and anti-oxidant properties of 
albumin 
 
 Oxidation is one of the most common post-translational modification of albumin 
in the diseased state. Therefore, we investigated the potential structural and functional 
consequences of the potential structural and functional consequences of oxidizing FA-
bound and FA-free HSA through exposure to hydrogen peroxide.  
 
4.2.1 The oxidation of albumin 
 
11.3 µL of 0.3% hydrogen peroxide was added to 10 mL of 2 mg/mL HSA in 10 mM 
PB, pH 7.5, and the reaction mixture was incubated at 40 ℃ for 1 hour. Then, the 
mixture was extensively dialyzed against standard buffer.  
 
4.2.2 Structural studies of oxidized HSA 
 
 The secondary structure of oxidized HSA-1 (ox-HSA-1) and oxidized HSA-2 (ox-
HSA-2) was studied utilizing far-UV CD spectroscopy following the method described in 
2.2.2. The CD spectra for the oxidized samples (Figure 4.5A) suggested a reduction in  
α-helical content as compared to that for unmodified HSA-1 and HSA-2. However, the 
HSA oxidation experiment involved incubation of the sample for one hour at 40 ℃. 
Therefore, there is the potential for aggregation of the protein sample during this 
experiment; such aggregation would cause a change in CD signal of the sample, which 
may or may not reflect changes in the helical content. Therefore, it is impossible to 
determine the degree of the change in protein structure due to the oxidation of the sample. 
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 A CD melt was then performed following the method in 2.2.2 to examine the 
stability of oxidized HSA-1 (Figure 4.5B) and oxidized HSA-2 (Figure 4.5C). The results 
for these samples were not significantly different than those for unmodified HSA-1 and 
HSA-2, and the oxidized samples showed hysteresis, demonstrating irreversible 
unfolding due to heating.  
 
 
 
Figure 4.5: The effect of oxidation on the secondary structure of HSA 
Far-UV CD spectra were recorded with 0.2 mg/mL ox-HSA-1 (blue) and ox-HSA-2 
(dark blue) dissolved in PB. These spectra were compared with those for HSA-1 (black) 
and HSA-2 (grey). 
 
 
4.2.3 The effect of oxidation on the anti-oxidant property of HSA 
 
LDL oxidation experiments were performed with the ox-HSA samples to compare 
the results to those found for the unmodified HSA samples. The results of these 
experiments are shown in Figure 4.6. Interestingly, unlike unmodified HSA, which 
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served as an anti-oxidant for LDL, oxidized HSA showed a pro-oxidant effect by 
decreasing the lag phase in LDL oxidation. This effect was similar for HSA-1 and HSA-2 
in that FA binding did not influence the pro-oxidant or anti-oxidant properties of HSA. 
The molecular basis for this effect of HSA on LDL oxidation needs further investigation. 
 
Figure 4.6: The effect of oxidation on the anti-oxidant properties of HSA 
 
LDL oxidation reactions were performed using the same procedure as described in 3.5: 
0.1 mg/mL of apoB in LDL was dissolved in 10mm PB at pH 7.5, and 0.1 mg/mL of ox-
HSA-1 (A) and ox-HSA-2 (B) were added. Then, 10 μm of CuSO4 was added. The 
absorbance of 234 nm UV light /was measured as a function of how much time had 
passed since the Copper Sulfate was added.  
 
A 
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4.3 Effects of glycation and glycoxidation of HSA on the structure and anti-oxidant 
properties of albumin 
 
 Samples of HSA glycated in vitro, with 1-5 mol hexose (as fructosamine) per mol 
albumin, were purchased from Sigma Aldrich. The structure of glycated HSA-1 (gly-
HSA-1) was studied utilizing the same techniques as those used to study the structure of 
the previous HSA samples.  
 
4.3.1 Structural studies of glycated albumin 
 The CD spectra of the glycated sample (Figure 4.7A) showed no significant 
difference in secondary structure as compared to the unmodified HSA sample. Therefore, 
the α-helical content of the glycated sample is very similar to that of unmodified albumin. 
The CD melt of the glycated sample showed a small low-temperature shift when 
compared to the CD melt of the unmodified protein, suggesting a small decrease in 
stability upon glycation. The significance of this effect and its molecular origin needs 
further investigation. difference when compared to the CD melt of the unmodified 
protein.  
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Figure 4.7: The effect of glycation on the secondary structure and stability of HSA 
(A) Far-UV CD spectra were recorded with 0.2 mg/mL gly-HSA-1 (red) dissolved in PB. 
These spectra were compared with those for HSA-1 (black). 
(B): 0.2 mg/mL of gly-HSA-1 was heated and then cooled at a rate of 2 °C/min while the 
CD signal at 222 nm (red) was measured. This melting curve was compared with that for 
HSA-1 (black). 
 
4.3.2 The pro-oxidant effect of glycated albumin  
LDL oxidation experiments were performed with the gly-HSA samples to 
compare the results to those found for the unmodified HSA samples. The results of these 
experiments are shown in Figure 4.8. Gly-HSA-1 had a pro-oxidant effect by decreasing 
the lag phase. 
A B 
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Figure 4.8: The effect of glycation on the anti-oxidant properties of HSA 
 
LDL oxidation reactions were performed using the same procedure as described in 3.5: 
0.1 mg/mL of apoB in LDL was dissolved in 10mm PB at pH 7.5, and 0.1 mg/mL of gly-
HSA-1 was added. Then, 10 μm of CuSO4 was added. The absorbance of 234 nm UV 
light was measured as a function of how much time had passed since the Copper Sulfate 
was added.  
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4.3.3 The glycoxidation of albumin  
In order to determine the structural and functional properties of glycoxidized HSA, 1 
mg/mL HSA in 10mM PB, pH 7.5, was incubated with 0.5 mM methylglyoxal purchased 
from Sigma-Aldrich (catalog number M0252) at 37 ℃ for 3 hours. Then the reaction 
mixture was dialyzed against standard phosphate buffer to remove excess methylglyoxal, 
and the glycoxidized albumin was stored at 4 ℃.  
The structure of glycoxidized HSA-1 (methylglyoxyl-HSA-1) and glycoxidized HSA-
2 (methylglyoxyl-HSA-2) was studied utilizing CD spectroscopy using the same method 
as that used to study the unmodified HSA-1 and HSA-2 samples; results of these 
experiments are shown in Figure 4.9. A steeper slope in the melting data observed for 
glycoxidized HSA-1 and glycoxidized HSA-2, as compared to unmodified HSA-1 and 
HSA-2, suggests that glycoxidation slightly increases the unfolding cooperativity of HSA 
regardless of the presence of bound FA. The significance of this effect and its underlying 
/mechanism requires further investigation. 
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Figure 4.9: The effect of glycoxidation on the secondary structure and stability of HSA 
(A,B) Far-UV CD spectra were recorded with 0.2 mg/mL methylglyoxyl-HSA-1 (dark 
green) and methylglyoxyl-HSA-2 (green) dissolved in PB. These spectra were compared 
with those for HSA-1 (black) and HSA-2 (black). 
(C,D): 0.2 mg/mL of methylglyoxyl-HSA-1 was heated and then cooled at a rate of 2 
°C/min while the CD signal at 222 nm (dark green) was measured. This melting curve 
was compared with that for HSA-1 (black). A similar experiment was performed to 
compare the thermal stability of methylglyoxyl-HSA-2 (green) with HSA-2 (black). 
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Then, LDL oxidation experiments were performed with the glycoxidized HSA 
samples to compare the results to those found for the unmodified HSA samples. The 
results of these experiments are shown in Figure 4.10. Like oxidized HSA-1 and HSA-2, 
glycoxidized HSA-1 and HSA-2 had a clear pro-oxidant effect and shortened the lag 
phase of LDL oxidation. The exact cause of this effect will be explored in future studies. 
 
 
 
 
Figure 4.10: The effect of glycoxidation on the anti-oxidant properties of HSA 
 
LDL oxidation reactions were performed using the same procedure as described in 3.5: 
0.1 mg/mL of apoB in LDL was dissolved in 10mm PB at pH 7.5, and 0.1 mg/mL of 
glycox-HSA-1 (light green) and glycox-HSA-2 (dark green) were added. Then, 10 μm of 
CuSO4 was added. The absorbance of 234 nm UV light /was measured as a function of 
how much time had passed since the Copper Sulfate was added. The reaction kinetics for 
glycox-HSA-1 (dark green) was then compared with those for HSA-1 (black), and the 
same was done for glycox-HSA-2 (green) and HSA-2 (black). 
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DISCUSSION 
   
 The results reported in this thesis show that fatty acid binding did not significantly 
alter the structural, stability or anti-oxidant properties of HSA. However, all post-
translational modifications of HSA, including cystenylation of Cys-34, glycation, 
oxidation, and glycoxidation, reversed the effect of HSA on LDL oxidation by copper: 
unmodified HSA was clearly anti-oxidant, while modified HSA acted as a pro-oxidant by 
decreasing the lag phase of LDL oxidation. To our knowledge, this effect has not been 
reported previously. The biochemical and structural basis underlying this general effect 
and its relevance to various oxidation processes in vivo remain to be determined in the 
future.  
 One important aspect of future studies is to consider the structural and functional 
effects of the post-translational modifications themselves, without the artefacts resulting 
from the experimental protocols involved. For example, the HSA glycation performed by 
Sigma-Aldrich, which did not involve protein heating, had very little effect on secondary 
structure observed by CD spectroscopy. This suggests that HSA heating used in the other 
methods to induce the other post-translational modifications caused significant changes to 
the protein structure. To eliminate these artefacts, in the future alternative methods will 
be used to introduce HSA modifications without heating. The results will help establish 
the molecular basis for the observed functional changes in modified HSA, such as its 
effects on LDL oxidation. 
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 Another important aspect for future studies is to consider the effects of these post-
translational modifications on drug binding and other properties of albumin besides its 
anti-oxidant function. Various post-translational modifications of HSA are known to exist 
in higher concentrations in various diseases states; for example, high levels of glycated 
HSA have been found in the serum of diabetic patients,21 and high levels of oxidized 
HSA are thought to potentially correlate with the development of advanced 
cardiovascular disease.41-3 Further in vitro experiments, building on the work done here, 
could elucidate potential mechanisms for altered function of such modified forms of 
albumin. 
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